Time-Dependent Bias of Tumor Growth Rate and Time to Tumor Regrowth.
作者信息
Mistry H B
机构信息
Manchester School of Pharmacy, Manchester, UK.
出版信息
CPT Pharmacometrics Syst Pharmacol. 2016 Nov;5(11):587. doi: 10.1002/psp4.12145. Epub 2016 Nov 10.
Abstract
摘要
相似文献
1
Time-Dependent Bias of Tumor Growth Rate and Time to Tumor Regrowth.肿瘤生长速率和肿瘤再生长时间的时间依赖性偏差
CPT Pharmacometrics Syst Pharmacol. 2016 Nov;5(11):587. doi: 10.1002/psp4.12145. Epub 2016 Nov 10.
2
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.贝伐珠单抗在 EGFR 突变型 NSCLC 异种移植模型中对抗 VEGF 依赖性耐药。
Int J Oncol. 2017 Aug;51(2):425-434. doi: 10.3892/ijo.2017.4036. Epub 2017 Jun 8.
3
Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.使用基于抗体的疗法靶向血管内皮生长因子驱动的血管生成。
Cancer J. 2008 May-Jun;14(3):170-7. doi: 10.1097/PPO.0b013e318178d9de.
4
Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.血管内皮生长因子A、其受体VEGFR-1、-2和-3以及共受体神经纤毛蛋白-1和-2的差异表达不能预测人星形细胞瘤中贝伐单抗的反应。
Neuro Oncol. 2016 Feb;18(2):173-83. doi: 10.1093/neuonc/nov288. Epub 2015 Nov 30.
5
Bevacizumab changes vascular structure and modulates the expression of angiogenic factors in recurrent malignant gliomas.贝伐单抗可改变复发性恶性胶质瘤的血管结构并调节血管生成因子的表达。
Brain Tumor Pathol. 2016 Apr;33(2):129-36. doi: 10.1007/s10014-016-0248-6. Epub 2016 Jan 29.
6
Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.三重抑制 EGFR、Met 和 VEGF 可抑制 HGF 触发的、携带 EGFR 突变的厄洛替尼耐药肺癌的复发。
J Thorac Oncol. 2014 Jun;9(6):775-83. doi: 10.1097/JTO.0000000000000170.
7
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.粒细胞集落刺激因子对血管破坏剂急性动员内皮祖细胞的作用。
Cancer Res. 2009 Oct 1;69(19):7524-8. doi: 10.1158/0008-5472.CAN-09-0381. Epub 2009 Sep 8.
8
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial.可溶性血管内皮生长因子受体1（sVEGFR1）、肝细胞生长因子（HGF）和血管内皮生长因子（VEGF）的动态可溶性变化促进化疗和贝伐单抗耐药：BECOX（GEMCAD 09-01）试验的一项前瞻性转化研究。
Tumour Biol. 2017 Jun;39(6):1010428317705509. doi: 10.1177/1010428317705509.
9
Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.血管内皮生长因子 A、胸苷酸合成酶和金属蛋白酶组织抑制剂 3 的基因表达在预测结直肠癌患者贝伐珠单抗治疗反应中的作用。
Dis Colon Rectum. 2011 Aug;54(8):1026-35. doi: 10.1097/DCR.0b013e31821c44af.
10
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.一项关于抗血管内皮生长因子抗体贝伐单抗用于转移性肾癌的随机试验。
N Engl J Med. 2003 Jul 31;349(5):427-34. doi: 10.1056/NEJMoa021491.
引用本文的文献
1
Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma.用于预测头颈部鳞状细胞癌生存结果的机制学习
CPT Pharmacometrics Syst Pharmacol. 2025 Mar;14(3):540-550. doi: 10.1002/psp4.13294. Epub 2024 Dec 25.
2
On the relationship between tumour growth rate and survival in non-small cell lung cancer.非小细胞肺癌中肿瘤生长速率与生存率的关系
PeerJ. 2017 Nov 29;5:e4111. doi: 10.7717/peerj.4111. eCollection 2017.
3
Exposure-Response Analysis of Necitumumab Efficacy in Squamous Non-Small Cell Lung Cancer Patients.奈昔单抗治疗鳞状非小细胞肺癌患者疗效的暴露-反应分析。
CPT Pharmacometrics Syst Pharmacol. 2017 Aug;6(8):560-568. doi: 10.1002/psp4.12209. Epub 2017 Jul 13.
4
A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.阿昔替尼在转移性肾细胞癌患者中的暴露量、疗效及安全性的药代动力学框架
CPT Pharmacometrics Syst Pharmacol. 2017 Jun;6(6):373-382. doi: 10.1002/psp4.12193. Epub 2017 May 26.
5
Model-Based Estimates of Tumor Growth Inhibition Metrics Are Time-Independent: A Reply to Mistry.基于模型的肿瘤生长抑制指标估计与时间无关：对米斯特里的回复。
CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):225. doi: 10.1002/psp4.12163. Epub 2017 Apr 11.
本文引用的文献
1
Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First-Line Gastric Cancer and Elevated Plasma VEGF-A.预测贝伐单抗联合化疗与单纯化疗用于一线胃癌且血浆VEGF-A升高患者的临床试验结果的模拟研究
CPT Pharmacometrics Syst Pharmacol. 2016 Jul;5(7):352-8. doi: 10.1002/psp4.12064. Epub 2016 Jul 12.
2
Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer.评估肿瘤大小反应指标，以预测一线转移性结直肠癌中西方和中国患者的总生存期。
J Clin Oncol. 2013 Jun 10;31(17):2110-4. doi: 10.1200/JCO.2012.45.0973. Epub 2013 May 6.
3
Immortal time bias in pharmaco-epidemiology.药物流行病学中的不朽时间偏倚。
Am J Epidemiol. 2008 Feb 15;167(4):492-9. doi: 10.1093/aje/kwm324. Epub 2007 Dec 3.
4
Time-dependent bias was common in survival analyses published in leading clinical journals.时间依赖性偏倚在主要临床杂志发表的生存分析中很常见。
J Clin Epidemiol. 2004 Jul;57(7):672-82. doi: 10.1016/j.jclinepi.2003.12.008.
Zotero 插件